The Health Care Select Sector SPDR ETF (NYSEARCA:XLV) pulled back from an all-time high on Thursday, closing marginally lower despite a record intraday print. The fund touched $169.71 before fading to end the session at $168.38, a 0.04% decline. That left the close 0.78% below the day's peak, signaling a potential rejection at resistance.
The reversal stood in sharp contrast to the broader market, which advanced to new records. The SPDR S&P 500 ETF Trust (NYSEARCA:SPY) rose 0.70% to $777.88, leaving health care underperforming the broad index by 0.74 percentage points. The Invesco QQQ Trust (NASDAQ:QQQ) gained 1.16%, and the iShares Russell 2000 ETF (NYSEARCA:IWM) added 0.26%.
Early attribution based on State Street's July 27 portfolio weights suggests the fund's ten largest holdings—which account for 61.63% of XLV—collectively contributed roughly 0.04 percentage point to performance. Eli Lilly (NYSE:LLY) was the top holding at 16.05% but slipped 0.92%, shaving about 0.15 point. Johnson & Johnson (NYSE:JNJ) rose 0.47%, adding 0.05 point. AbbVie (NYSE:ABBV) gained 0.83% and contributed 0.06 point. UnitedHealth Group (NYSE:UNH) fell 1.61%, trimming 0.10 point. Merck (NYSE:MRK) advanced 1.98%, adding 0.11 point.
Other top components were mixed: Thermo Fisher Scientific (NYSE:TMO) declined 1.21%, Amgen (NASDAQ:AMGN) rose 0.40%, Abbott Laboratories (NYSE:ABT) added 0.32%, Gilead Sciences (NASDAQ:GILD) gained 1.67%, and Pfizer (NYSE:PFE) climbed 1.86%. The aggregate contribution from the top ten was approximately +0.04 point.
The remaining 38.37% of the fund subtracted roughly 0.08 point, implying that weakness was broad-based beyond the largest names. This suggests the late-day fade was not confined to a few stocks but reflected a broader softness in mid-sized and smaller health care holdings.
On a sector basis, pharmaceuticals represented 37.90% of XLV as of July 27, followed by providers and services at 18.72%, biotechnology at 18.28%, and equipment and supplies at 15.64%. This composition means that falling Treasury yields—which often support defensive sectors—did not uniformly lift health care on Thursday.
Analyst sentiment for the top five holdings remains bullish, though expected upside varies widely. Eli Lilly has 18 buy ratings and a consensus target implying 13.95% upside. Johnson & Johnson has 13 buys and 8.25% upside. AbbVie has 19 buys and 11.48% upside. UnitedHealth has 16 buys and 20.70% upside, while Merck has 13 buys but only 2.50% projected upside.
The broader market backdrop was positive: the S&P 500 rose 0.65% to a record close of 7,798.99, the Nasdaq gained 0.81%, and the Dow added 0.13%. Seven of eleven S&P sectors advanced, led by communication services and real estate. Producer prices were flat month-over-month in July, with goods prices down 0.7% and services up 0.2%. Annual producer inflation slowed to 4.7% from 5.5%, tempering expectations for a near-term Federal Reserve rate hike.
Technology continues to dominate market leadership. Jay Hatfield, CEO of Infrastructure Capital Advisors, characterized the tech rally as "an earnings boom, not a bubble." The divergence in health care underscores that lower yields are not lifting all sectors equally.
The key test for XLV comes on Friday: it needs to reclaim the $169.71 level with broader participation among its smaller components. Without that, Thursday's action may be viewed as an intraday rejection rather than a confirmed breakout.
